Edaravone suspension for oral administration

TW202633604APending Publication Date: 2026-08-16TANABE PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115100329
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-02
Filing Date
2019-11-01
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001073347_001
    Figure TWG2TA001073347_001
  • Figure TWG2TA001073347_002
    Figure TWG2TA001073347_002
Patent Text Reader

Abstract

This invention provides with a formulation of Edarabone suspension for oral administration having an excellent bioavailability. It is expected that the suspension would reduce a burden required for a patient of ALS and his caregiver.
Need to check novelty before this filing date? Find Prior Art